Sunshine Novo (688621.SH) announced first-quarter results, net profit of 72.7538 million yuan, an increase of 51.77% over the previous year
According to Zhitong Finance App News, Sunshine Nuohe (688621.SH) released its report for the first quarter of 2024. The company's revenue was 252 million yuan, up 8.53% year on year; net profit attributable to shareholders of listed companies was 72.7538 million yuan, up 51.77% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 666.201 million yuan, an increase of 41.68% year on year; basic earnings per share were 0.65 yuan/share.
China Merchants Securities: Demand for outsourcing generic drug development services increases, and the performance of listed companies related to generic CRO maintains a relatively rapid growth rate
From a long-term development perspective, imitation CRO related companies are expected to fully benefit from advanced market demand, business model innovation, and customer base expansion, and achieve continuous growth in performance. First-tier enterprises are expected to increase their market share in industrial upgrading competition.
Sunshine Novo (688621.SH): Ruiying Management, Ruiying Investment, Guangzhou Zhengda, Haida Mingde, and Huipu Zofang reduced their total holdings by 1.1855%
Glonghui, March 1, 丨 Sunshine Novo (688621.SH) announced that the company received the “Notice Letter on Implementation Progress and Equity Changes in the Shares Reduction Plan of Beijing Sunshine Nuohe Pharmaceutical Research Co., Ltd.” issued by shareholders Ruiying Management, Ruiying Investment, Guangzhou Zhengda, Haida Mingde, and HPP ZF through centralized bidding transactions. The number of shares reduced by 1.1855% of the company's total share capital was 1.1855% of the company's total share capital. The current holdings reduction plan has expired.
Sunshine Novo (688621.SH)'s net profit of 194 million yuan in 2023 increased 24.43% year-on-year
Sunshine Novo (688621.SH) disclosed its 2023 annual performance report. During the reporting period, the company achieved operating income...
Sunshine Novo (688621.SH): The company currently has 36,300 square meters of R&D laboratory, with more than 80% of the laboratory area already in use
Gelonghui, January 2丨Sunshine Nuohe (688621.SH) received a survey from specific subjects and said that the company currently has 36,300 square meters of R&D laboratory, and more than 80% of the laboratory area has been put into use. The company has established synthesis laboratories, testing laboratories, microbiology laboratories, etc. at its headquarters in Changping, Beijing, including laboratories for the development of various dosage forms; Beijing Fengtai has built a clinical phase I-III trial center and PK/PD analysis laboratory for small chemical molecules and biomacromolecules; Beijing Daxing and Yizhuang International Biomedical Park have established separate pediatric drug platforms and TDS drug laboratories for childhood diseases
Sunshine Nuohe (688621.SH): More than 40 new self-developed projects were set up in the first half of the year, and the total number has exceeded 290
Gelonghui, December 6 | Sunshine Nuohe (688621.SH) recently stated during a survey by institutional investors that in the first half of 2023, the company set up more than 40 new self-research projects, totaling more than 290; in the company's participation in R&D and independent R&D projects, a total of 3 new drug projects have passed NMPA approval to enter clinical trials, 47 drug applications have been accepted for marketing registration, and 7 consistency evaluations have been accepted; with mature R&D technology platforms and project reporting capabilities, the company has signed joint development project agreements with many enterprises, including 6 types of equity, have been approved, including approval Amopressin injection, pimex
Novo Sunshine (688621.SH): Provides phase I-IV clinical trial research services, bioequivalence (BE) testing services, etc.
Gelonghui, December 6|Sunshine Nuohe (688621.SH) recently stated in receiving research from institutional investors that in terms of clinical trials, the company provides phase I-IV clinical trial research services, bioequivalence (BE) testing services, etc. Currently, the company has laid out 7-8 pipelines, nearly 20 improved new drugs, and established more than 200 generic drug projects for peptides and peptidoids. The company has established four major professional platforms. Clinical trial R&D platforms (two major R&D platforms under medical and clinical operations), data management and statistical analysis platforms, SMO platforms, third-party inspection platforms, and 19 regular offices have been set up nationwide
Sunshine Novo (688621.SH): Currently, the main types of customers include domestic pharmaceutical companies that are vigorously expanding Biotech companies, etc.
Gelonghui, December 6|Sunshine Nuohe (688621.SH) recently stated during a survey from institutional investors that the company's customer structure is scattered and currently has locations in East China, Central China, South China, Southwest China, and Northeast China. Currently, the company's main customer types include domestic pharmaceutical companies, while also vigorously expanding Biotech companies and innovative pharmaceutical companies.
Sunshine Novo (688621.SH): The company has not yet launched business related to AI technology
On November 15, Gelonghui (688621.SH) stated on the investor interactive platform that the company has not yet carried out business related to AI technology. If the company has relevant plans, it will promptly fulfill its review and information disclosure obligations in strict accordance with regulatory regulations.
The shareholding ratio of Sunshine Novo (688621.SH) shareholder Heidalminde and his co-actors fell below 5%
Sunshine Nuohe (688621.SH) announced that the company's shareholders Haida Mingde, Rui Ying Investment, Guangzhou Zhengda, Huipu Nofang...
Sunshine Novo (688621.SH): Product highlights under development include complex injections, peptide preparations, topical delivery and transdermal absorption drugs, pediatric drugs, rare disease drugs, and other special formulations
Gelonghui, November 10|Sunshine Nuohe (688621.SH) said in an investor survey that the company's generic drugs and innovative drugs are different R&D teams. The research fields they undertake within the company are different, and there are few team intersections. In terms of innovative drugs, the products being developed by the company are mainly used in the fields of analgesia, nephropathy and dialysis, tumor support, cardiovascular and cerebrovascular, antibacterial drugs, etc.; in terms of improved new drugs, the company is carrying out technology research and development and industrial transformation research on drug delivery systems, focusing on research and development of long-acting microspherical preparations, sustained-release preparations, etc.; in terms of generic drugs, the products being developed by the company include complex injections and peptides
Sunshine Novo (688621.SH) plans to acquire 30% of Novo Shengtai's shares for 120 million yuan to hold all of its shares
Sunshine Nuohe (688621.SH) announced that the company and its holding subsidiary Chengdu Nuohe Shengtai Biotechnology Co., Ltd...
Sunshine Novo (688621.SH): The company has a competitive advantage in the specialization of some core technologies
GLONGHUI September 22丨An investor asked Sunshine Nuohe (688621.SH): Hello! What are the company's competitors, and how can the company break the game in the face of rival encirclement? Sunshine Nuohe replies: Dear investors, hello! Currently, the company's competitors in the industry mainly include listed companies such as Tiger Pharmaceutical, Medici, Northlog, and Baicheng Pharmaceutical. Compared with other competitors in the same industry, the company has a competitive advantage in terms of the specialization of some core technologies. Focusing on the integrated strategy of preclinical+clinical research, the company continues to deepen integrated development, and extends the current advantages of integration from chemical drugs to biopharmaceuticals and China
Sunshine Novo (688621.SH): The company has gradually developed into a comprehensive pre-clinical and clinical R&D service CRO with strong domestic market competitiveness
GLONGHUI September 22丨Some investors asked Sunshine Nuohe (688621.SH): Has the company's market position improved further in the new year? Sunshine Novo replies: Hello! The company was founded in 2009 and is one of the earliest CRO companies (Contract Research Organization, Contract Research Organization) in China to provide drug research and development services to the outside world. The company has 36,300 square meters of R&D laboratories, of which the laboratory area that has been put into use is 31,700 square meters, and the laboratory area under construction is 0.46 million
Sunshine Novo (688621.SH): The company will plan to expand fields in due course according to its own business development plans
GLONGHUI September 22丨Some investors asked Sunshine Nuohe (688621.SH): The company's innovative drug sector has added quite a bit of business, but it still lacks a very important GLP safety review. Can it be completed as soon as possible in the future? Sunshine Nuohe replies: Dear investors, hello! Thank you for your suggestions to the company. The company will plan to expand the field in due course according to its own business development plan.
Sunshine Novo (688621.SH): There is no information that should have been disclosed but not disclosed
GLONGHUI September 22丨Some investors asked Sunshine Novo (688621.SH): How many new orders did the company sign in the first half of the year? Why isn't such important data published? Sunshine Novo replied: Dear investors, hello! The company filled in the semi-annual report information in strict accordance with the requirements for the preparation of the 2023 semi-annual report of the Shanghai Stock Exchange. There is no information that should be disclosed but not disclosed. Thank you!
Sunshine Novo (688621.SH) shareholder Haida Minde and his co-actors reduced their holdings by a total of 1%
Sunshine Novo (688621.SH) announced that the company's shareholder Hangzhou Haida Mingde Venture Capital Partnership (Limited...
Sunshine Novo (688621.SH) announced first-half results, net profit of 118 million yuan, an increase of 35.03%
Sunshine Novo (688621.SH) released the 2023 semi-annual report. The company's revenue was 461 million...
Sunshine Novartis (688621.SH): Five shareholders have reduced their holdings by a cumulative total of 6881,000 shares, and the holdings reduction range has come to an end
GLONGHUI, August 9丨Sunshine Nuohe (688621.SH) announced that as of August 9, 2023, Ruiying Investment, Guangzhou Zhengda, Haida Mingde, and Hewlett-Packard have reduced their holdings of the company by a total of 688,057 shares through centralized bidding transactions (188,057 shares reduced before equity distribution, reduced by 500,000 shares after equity distribution), accounting for 0.6815% of the company's total share capital. The current holdings reduction plan range has come to an end.
Sunshine Novartis (688621.SH): Selected as the fifth batch of “little giant” companies specializing in new and exclusive products by the Ministry of Industry and Information Technology
On July 20丨Sunshine Nuohe (688621.SH) announced that recently, according to the “Notice Concerning the Fifth Batch of Specialized and New “Little Giants” Enterprises in Beijing and the Second Batch of Specialized and Exquisite New “Little Giants” Reviewed and Approved Enterprises, the company was selected as the fifth batch of exclusive new “little giant” enterprises.
No Data